PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30344659-2	2018	The aim of the present study was to access the class I-selective histone deacetylase (HDAC) inhibitor (HDACI) MGCD0103 on the expression levels of Bcl-2, nuclear factor (NF)-kappaB and programmed death-ligand 1 (PD-L1) in CHL, to explore the possible therapeutic value of MGCD0103 in combined relative target drugs for patients with CHL.	mocetinostat	110-118	BCL2 apoptosis regulator	Homo sapiens	147-152	
30344659-4	2018	The results demonstrated that MGCD0103 could induce cell apoptosis and cell cycle arrest, down-regulate Bcl-2 and increase NF-kappaB and PD-L1 expression levels in L1236 and L428 cell lines.	mocetinostat	30-38	BCL2 apoptosis regulator	Homo sapiens	104-109	
30344659-5	2018	MGCD0103 decreases Bcl-2 levels and upregulates PD-L1, which indicates that the combined use of HDACIs and a PD-L1 inhibitor in theory may improve treatment outcomes in patients with CHL.	mocetinostat	0-8	BCL2 apoptosis regulator	Homo sapiens	19-24